This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jongsma, J. Articles by van Steenbrugge, G. J. Search for Related Content PubMed PubMed Citation Articles by Jongsma, J. Articles by van Steenbrugge, G. J.

Androgen Deprivation of the Prohormone Convertase-310 Human Prostate Cancer Model System Induces Neuroendocrine Differentiation¹

Departments of Experimental Urology [J. J., M. H. O., M. A. N., W. M. V. W., F. H. S., G. J. v. S.] and Pathology [T. H. v. d. K.], Josephine Nefkens Institute, Erasmus University, 3000 DR Rotterdam, and Department of Animal Physiology [G. J. M. M.], University of Nijmegen, Toernooiveld, 6525 ED Nijmegen, the Netherlands

Neuroendocrine (NE) cells are androgen-independent cells and secrete growth-modulating neuropeptides via a regulated secretory pathway (RSP). We studied NE differentiation after androgen withdrawal in the androgen-dependent prostate cancer xenograft PC-310. Expression patterns of chromogranin A, secretogranin III, and prohormone convertase-1 were analyzed at both protein and mRNA level to mark the kinetics of NE differentiation both in vivo and in vitro. PC-310 tumor-bearing nude mice were killed at 0, 2, 5, 7, 14, and 21 days postcastration. PC-310C cultures initiated from collagenase-treated tumor tissue could be maintained up to four passages, and androgen-deprivation experiments were performed similarly. PC-310 tumor volumes decreased by 50% in 10 days postcastration. Proliferative activity and prostate-specific antigen (PSA) serum levels decreased to zero postcastration, whereas PSA levels in PC-310C culture media first decreased and subsequently increased after 5 days. In vivo, androgen receptor (AR) expression decreased initially but returned to control level from 5 days postcastration on. CgA, secretogranin III, and secretogranin V expression increased in vivo from 5 days postcastration on. Subsequently, prohormone convertase-1 and peptidyl -amidating monooxygenase as well as the vascular endothelial growth factor were expressed from 7 days postcastration on, and, finally, growth factors such as gastrin-releasing peptide and serotonin were expressed in a small part of the NE cells 21 days postcastration. The PC-310 tumors did not show colocalization of the AR on the NE cells in the tumor residues after 21 days.

As in the PC-310 xenograft, NE differentiation was induced and AR expression relapsed after prolonged androgen suppression in PC-310C. For PC-310C cells, this relapse was associated with the secretion of PSA. PC-310C is the first culture of human prostatic cancer cells having the NE phenotype. The PC-310 model system is a potential androgen-dependent model for studying the role of NE cells in the progression of clinical prostate cancer. Androgen deprivation of NE-differentiated prostate cancer may induce the formation of both NE- and AR-positive dormant tumor residues, capable of actively producing NE growth factors via a RSP, possibly leading to hormone refractory disease.

This article has been cited by other articles:

				D. E. Frigo and D. P. McDonnell Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation Mol. Cancer Ther., March 1, 2008; 7(3): 659 - 669. [Abstract] [Full Text] [PDF]

				T.-C. Yuan, S. Veeramani, and M.-F. Lin Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells Endocr. Relat. Cancer, September 1, 2007; 14(3): 531 - 547. [Abstract] [Full Text] [PDF]

				C.-P. Liao, C. Zhong, G. Saribekyan, J. Bading, R. Park, P. S. Conti, R. Moats, A. Berns, W. Shi, Z. Zhou, et al. Mouse Models of Prostate Adenocarcinoma with the Capacity to Monitor Spontaneous Carcinogenesis by Bioluminescence or Fluorescence Cancer Res., August 1, 2007; 67(15): 7525 - 7533. [Abstract] [Full Text] [PDF]

				R. J. Epstein Maintenance Therapy to Suppress Micrometastasis: The New Challenge for Adjuvant Cancer Treatment Clin. Cancer Res., August 1, 2005; 11(15): 5337 - 5341. [Abstract] [Full Text] [PDF]

				M P Roudier, L D True, R L Vessella, and C S Higano Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity J. Clin. Pathol., March 1, 2004; 57(3): 321 - 323. [Abstract] [Full Text] [PDF]